TY - JOUR
T1 - The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services
T2 - a systematic review and meta-analysis
AU - Shah, Richa
AU - Hanna, Nader Mounir
AU - Loo, Ching Ee
AU - David, Michael
AU - Mafra, Allini
AU - Fink, Hanna
AU - McFerran, Ethna
AU - Garcia, Montse
AU - Ghodssighassemabadi, Robabeh
AU - Acharya, Suryakanta
AU - Niyibaga, Jean
AU - Langselius, Oliver
AU - Frick, Clara
AU - Lasebikan, Nwamaka
AU - Vignat, Jerome
AU - Steinberg, Julia
AU - Hughes, Suzanne
AU - Kircher, Colleen Elizabeth
AU - Goldie, Catherine Lindsay
AU - Egger, Sam
AU - Sullivan, Richard
AU - Ginsburg, Ophira
AU - Bray, Freddie
AU - Caruana, Michael
AU - Hui, Harriet
AU - Ilbawi, André Michel
AU - Canfell, Karen
AU - Soerjomataram, Isabelle
N1 - Funding
2021/1187438-0/World Health Organization (WHO)
Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2025.
PY - 2025/1
Y1 - 2025/1
N2 - The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on cancer services, including diagnosis, diagnostic procedures, screening, treatment and supportive and palliative care. Based on data from 245 articles in 46 countries, we observed declines in the number of cancer screening participation (39.0%), diagnoses (23.0%), diagnostic procedures (24.0%) and treatment (28.0%), ranging from a 15.0% decline for radiotherapy to a 35.0% decline for systemic treatment during the pandemic compared to during the prepandemic period. Medium-human development index (HDI) category countries experienced greater reductions than high- and very-high-HDI countries. Missing data from low-HDI countries emphasize the need for increased investments in cancer surveillance and research in these settings.
AB - The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on cancer services, including diagnosis, diagnostic procedures, screening, treatment and supportive and palliative care. Based on data from 245 articles in 46 countries, we observed declines in the number of cancer screening participation (39.0%), diagnoses (23.0%), diagnostic procedures (24.0%) and treatment (28.0%), ranging from a 15.0% decline for radiotherapy to a 35.0% decline for systemic treatment during the pandemic compared to during the prepandemic period. Medium-human development index (HDI) category countries experienced greater reductions than high- and very-high-HDI countries. Missing data from low-HDI countries emphasize the need for increased investments in cancer surveillance and research in these settings.
UR - http://www.scopus.com/inward/record.url?scp=85214108653&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/39747650/
U2 - 10.1038/s43018-024-00880-4
DO - 10.1038/s43018-024-00880-4
M3 - Article
C2 - 39747650
AN - SCOPUS:85214108653
SN - 2662-1347
VL - 6
SP - 194
EP - 204
JO - Nature Cancer
JF - Nature Cancer
IS - 1
M1 - 869752
ER -